CClinicalTrials.gg
CompletedNCT07456683WACUpdated Mar 6, 2026

The Effect of Water With Anti-Inflammatory Capabilities on the Inflammatory Response to Heavy Resistance Exercise

An interventional study of We made a water with berry essence volatiles (cranberry, blackberry, and blueberry). This was consumed for 6 weeks. in Systemic Inflammation, Hydration and Resting Metabolism, sponsored by University of Arkansas, Fayetteville. Completed at 1 site in United States. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-06.

Sponsored by University of Arkansas, Fayetteville · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years 9 months after the study started (first participant enrolled May 2021, registered Mar 2026).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 39 Years
Sex
All
01

Study summary

The purpose of this research is to assess the anti-inflammatory effects of berry-flavored water in response to an acute bout of exercise. This investigation is part of a larger collaborative project between the Exercise Science Research Center, the Center for Human Nutrition, and the University of Arkansas Sensory Science Center, which seeks to examine the potential of waters infused with naturally occurring bioactive anti-inflammatory volatile compounds to improve overall health. We expect that this water infused with natural bioactive berry volatile compounds will demonstrate preventive physiological benefits in relation to systemic inflammation, including a decreased level of baseline (resting) inflammation and attenuated post-exercise inflammation.

Read the detailed description

Participants will be asked to refrain from eating berries for 48 hours, drinking alcohol for 24 hours and consuming caffeine for 12 hours prior to reporting for their baseline test, and all subsequent visits to the lab. This will be confirmed via self-report form. All visits to the lab will be completed between the hours of 0700 and 0900 in order to ensure each participant arrives fasted. For baseline testing, occurring on Day 0, participants will determine their 1 repetition maximum (1RM) back squat using standardized protocols set forth by the National Strength and Conditioning Association. Following their 1RM determination, participants will receive a dual energy X-ray absorption scan to determine body composition. On Day 6, 24 hours leading into the next visit, participants will be asked to record food and fluid intake via a standard diet log and collect urine output in a urine collection jug for 24 hours. This visit will require participants to come to the lab to pick up a diet log and urine collection jug. On Day 7, participants will report to the lab and offer a blood sample from an antecubital vein. They will then undergo a standardized warm up, which will consist of 5 minutes at a self-selected pace on a treadmill, followed by two sets of 10 body weight squats, 10 glute bridges, and 10 lunges on each leg. Following the warmup, participants will complete an acute heavy resistance exercise protocol (AHREP), which will consist of 6x10 repetition maximum (10RM) back squat, with two minutes rest between sets. This protocol was chosen due to its effectiveness in eliciting a large inflammatory response in other studies. Working set load will be estimated by taking 75% the 1RM weight, which estimates 10RM. Following each set, participants will be asked to rate their effort on a scale of 6-20. Immediately following completion of the exercise, participants will provide another blood sample, before a standardized cool down where they will be asked to walk at a comfortable pace on a treadmill. On Day 8, approximately 24 hours after completion of AHREP1, participants will return to the lab for another blood draw and complete a muscle soreness questionnaire and a self-reported muscle function questionnaire. Prior to leaving the lab, they will be given 42 bottles containing 16.9ozs of berry-infused water, or plain water, which they will be instructed to drink 2 times per day, starting after they leave the lab. On Day 9, approximately 48 hours after completion of AHREP1, the participants return to the lab for another blood draw and another muscle soreness questionnaire. On Day 27, 24 hours leading into the next visit, participants will be asked to record food and fluid intake via a standard diet log and collect urine output in a urine collection jug for 24 hours. This visit will require participants to come to the lab to pick up a diet log and urine collection jug. On Day 28 of the study, participants will return to the lab as a compliance check. They will receive another 42 drinks, (berry-infused water or plain water) as well as offer a blood sample. They will fill out a Pittsburg Sleep Quality Index form and a Profile of Mood States form. On Day 41, 24 hours leading into the next visit, participants will be asked to record food and fluid intake via a standard diet log and collect urine output in a urine collection jug for 24 hours. This visit will require participants to come to the lab to pick up a diet log and urine collection jug. On Day 42 of the study, participants return to the lab and offer a blood sample. They will then undergo a standardized warm up. Following the warmup, participants will complete a second AHREP. Immediately following completion of the exercise, participants will provide another blood sample, before a standardized cool down where they will be asked to walk at a comfortable pace on a treadmill. On Day 43, approximately 24 hours after completion of AHREP2, participants will return to the lab for another blood draw and complete a muscle soreness questionnaire and a self-perceived function questionnaire. On Day 44, approximately 48 hours after completion of AHREP2, the participants return to the lab for another blood draw and another muscle soreness questionnaire and self-perceived function questionnaire. At this point the participation in the study will be concluded and participants compensated for their efforts.

02

Conditions studied

  • Systemic Inflammation
  • Hydration
  • Resting Metabolism
03

In context

Lead sponsor

University of Arkansas, Fayetteville is the lead sponsor of 29 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 39 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Sedentary to moderately active, as defined by the International Physical Activity Questionnaire (IPAQ)

Exclusion criteria

Exclusion Criteria:

  • Kidney, liver, cardiac, or immune conditions that may compromise their health Not used to lifting weights more than 1 time per month. Participants identified as being 'high fruit/vegetable consumers' will also be excluded from the study because they habitually consume polyphenols and antioxidants already exhibiting anti-inflammatory effects that would compromise our findings.

A history of fainting from routine blood draws.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Consuming WAC beverage for 6 weeks

    Other: We made a water with berry essence volatiles (cranberry, blackberry, and blueberry). This was consumed for 6 weeks.

Interventions

  • OtherWe made a water with berry essence volatiles (cranberry, blackberry, and blueberry). This was consumed for 6 weeks.

    Participants consumed 1L of special water every day for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Inflammation

    Innflammatory biomarkers

    Time frame: Baseline, Post-lifting, day 1 post, day 2 post, 3-week post, baseline 2, post-lifting 2, day1 (2), day 2 (2). All over a 6-wk period

07

Study locations

1 site
  • University of Arkansas Exercise Science Research Center
    Fayetteville, Arkansas 72701, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07456683
Lead sponsor
University of Arkansas, Fayetteville
Responsible party
Brendon P. McDermott (Professor, University of Arkansas, Fayetteville) — Principal investigator
First posted
Mar 6, 2026
Start date
May 17, 2021
Primary completion
Feb 10, 2024
Completion
Feb 10, 2024
Last update
Mar 6, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion